-0.81%
-3.61%
-3.84%
-24.87%
-28.07%
-28.51%
-24.12%
AI Spotlight on BMRN
Company Description
BioMarin Pharmaceutical Inc.develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria.The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
BioMarin Pharmaceutical Inc.has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd.The company was incorporated in 1996 and is headquartered in San Rafael, California.
Market Data
| Last Price | 63.36 |
| Change Percentage | -0.81% |
| Open | 63.88 |
| Previous Close | 63.88 |
| Market Cap ( Millions) | 12075 |
| Volume | 1132691 |
| Year High | 94.85 |
| Year Low | 60.63 |
| M A 50 | 64.92 |
| M A 200 | 76.23 |
Financial Ratios
| FCF Yield | 2.49% |
| Dividend Yield | 0.00% |
| ROE | 6.22% |
| Debt / Equity | 11.13% |
| Net Debt / EBIDTA | -14.34% |
| Price To Book | 2.23 |
| Price Earnings Ratio | 37.44 |
| Price To FCF | 40.13 |
| Price To sales | 4.39 |
| EV / EBITDA | 23.66 |
News
- Jan -27 - BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
- Jan -23 - BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
- Jan -22 - These 4 Stocks Boast Impressive Interest Coverage Ratio
- Jan -14 - 5 Biotech Stocks Worth Adding to Your Portfolio in 2025
- Jan -13 - BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
- Jan -13 - Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know
- Jan -06 - These 4 Stocks Boast Impressive Interest Coverage Ratios
- Jan -06 - BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
- Jan -03 - 10 Magnificent Stocks That Can Make You Richer in 2025
- Jan -02 - BMRN or TECH: Which Is the Better Value Stock Right Now?
- Nov -22 - Can BioMarin Stock Live Up to Wall Street's High Expectations?
- Nov -21 - Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
- Nov -16 - BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
- Nov -06 - BioMarin to Participate in Three Upcoming Investor Conferences
- Nov -04 - BioMarin (BMRN) Upgraded to Buy: Here's Why
- Nov -04 - BMRN vs. INCY: Which Stock Is the Better Value Option?
- Oct -30 - BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
- Oct -30 - BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript
- Oct -29 - BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Oct -29 - BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Therapies
Expected Growth : 11 %
What the company do ?
BioMarin Pharmaceutical Inc.'s Innovative Therapies involve developing and commercializing novel treatments for rare genetic diseases, such as enzyme replacement therapies and gene therapies.
Why we expect these perspectives ?
BioMarin's innovative therapies drive 11% growth, fueled by increasing adoption of rare disease treatments, strong pipeline of gene therapies, and expanding commercial presence in key markets. Additionally, strategic partnerships and investments in research and development further accelerate growth.
Biomarin Pharmaceutical Inc. Products
| Product Range | What is it ? |
|---|---|
| Vimizim | An enzyme replacement therapy for the treatment of Mucopolysaccharidosis type IVA (MPS IVA), a rare genetic disorder. |
| Naglazyme | An enzyme replacement therapy for the treatment of Mucopolysaccharidosis type VI (MPS VI), a rare genetic disorder. |
| Kuvan | A medication used to reduce the blood levels of phenylalanine in patients with phenylketonuria (PKU), a rare genetic disorder. |
| Firdapse | A medication used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. |
| Brineura | An enzyme replacement therapy for the treatment of CLN2 disease, a rare genetic disorder. |
| Palynziq | A medication used to reduce the blood levels of phenylalanine in patients with phenylketonuria (PKU), a rare genetic disorder. |
BioMarin Pharmaceutical Inc.'s Porter Forces
Threat Of Substitutes
BioMarin Pharmaceutical Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for rare genetic disorders. However, the company's focus on developing innovative and life-changing treatments reduces the threat of substitutes.
Bargaining Power Of Customers
BioMarin Pharmaceutical Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatment options for rare genetic disorders.
Bargaining Power Of Suppliers
BioMarin Pharmaceutical Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and manufacturing services. However, the company's dependence on a few key suppliers for certain components increases the bargaining power of suppliers.
Threat Of New Entrants
BioMarin Pharmaceutical Inc. has a low threat of new entrants due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development, manufacturing, and regulatory approvals.
Intensity Of Rivalry
BioMarin Pharmaceutical Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry. The company faces competition from other biotechnology companies, as well as from pharmaceutical companies that are expanding into the rare genetic disorder space.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 18.12% |
| Debt Cost | 3.95% |
| Equity Weight | 81.88% |
| Equity Cost | 5.65% |
| WACC | 5.34% |
| Leverage | 22.13% |
BioMarin Pharmaceutical Inc. : Quality Control
BioMarin Pharmaceutical Inc. passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is … |
| CYTK | Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily … |
| PTCT | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in … |
| AGIO | Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) … |
| SWTX | SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Agios Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
PTC Therapeutics
A-Score
1-Year Total Return ->
🥉
BioMarin Pharmaceutical
A-Score
1-Year Total Return ->
4
Rhythm Pharma
A-Score
1-Year Total Return ->
5
Cytokinetics
A-Score
1-Year Total Return ->
6
